Loading...
Larrañaga 1 2 Lorea Mar‑Barrutia 5 Myriam Soto‑Gordoa 6 0 Unidad de Gestión Sanitaria, Hospital 'Alto Deba' , Avenida Navarra 16, 20500 Mondragón , Spain 1 Basque Health Service (Osakidetza), Debagoiena ... /s13195‑022‑01111‑7. Additional file 1: Table S1. Dementia incidence with confidence intervals (CIs). Obtained from reference 25. Mar J, Gorostiza A, Arrospide A, Larrañaga I, Alberdi A, Cernuda C, et al
. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 1. Mar J , Soto-Gordoa M , Arrospide A , Moreno-Izco F , Martínez-Lage P ... - 6 . 12. Soto-Gordoa M , Arrospide A , Moreno-Izco F , Martinez-Lage P , Castilla I , Mar J . Projecting burden of dementia in Spain, 2010-2050: impact of modifying risk factors . J Alzheimers Dis
TDP-43 type C is one of the pathological forms of frontotemporal lobar degeneration (FTLD) and mainly associated clinically with the semantic variant of primary progressive aphasia (svPPA). We aimed to define in vivo the sequential pattern of neuroanatomical involvement in a cohort of patients with FTLD-TDP type C pathology. We extracted the volumes of a set of cortical and...
TDP-43 type C is one of the pathological forms of frontotemporal lobar degeneration (FTLD) and mainly associated clinically with the semantic variant of primary progressive aphasia (svPPA). We aimed to define in vivo the sequential pattern of neuroanatomical involvement in a cohort of patients with FTLD-TDP type C pathology. We extracted the volumes of a set of cortical and...
BackgroundApoJ/clusterin is a multifunctional protein highly expressed in the brain. The implication of ApoJ in β-amyloid (Aβ) fibrillization and clearance in the context of Alzheimer’s disease has been widely studied, although the source and concentration of ApoJ that promotes or inhibits Aβ cerebral accumulation is not clear yet. ApoJ is abundant in plasma and approximately 20...
Solé1, Guillem Colell1, Anna Bonaterra1, Jose Luis Sánchez-Quesada2, 3, Joan Montaner1, Daniel Maspoch4, 5, Mary Cano-Sarabia4, 5 and Mar Hernández-Guillamon1Email author Alzheimer's Research
Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited attention, with AD trials persistently recruiting lower numbers of women than the population...
. Clinicoecon Outcomes Res . 2011 ; 3 : 189 - 95 . 14. Mar J , Arrospide A , Comas M. Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model . Value Health . 2010 ; 13 : 69 ... population-based cohorts: Neurologic Diseases in the Elderly Research group . Neurology . 2000 ; 54 : S4 - 9 . 17. Karnon J , Stahl J , Brennan A , Caro JJ , Mar J , Möller J , et al. Modeling using discrete
There is an increasing role for biological markers (biomarkers) in the understanding and diagnosis of neurodegenerative disorders. The application of imaging biomarkers specifically for the in vivo investigation of neurodegenerative disorders has increased substantially over the past decades and continues to provide further benefits both to the diagnosis and understanding of...
There is an increasing role for biological markers (biomarkers) in the understanding and diagnosis of neurodegenerative disorders. The application of imaging biomarkers specifically for the in vivo investigation of neurodegenerative disorders has increased substantially over the past decades and continues to provide further benefits both to the diagnosis and understanding of...
To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. Both plasma Aβ42/40 ratio alone or combined...
, Arantzazu Arrospide2, 3, Fermín Moreno-Izco4 and Pablo Martínez-Lage5 Alzheimer's Research & Therapy20157:2 https://doi.org/10.1186/s13195-014-0079-9 © Mar et al.; licensee BioMed Central. 2015 ... , Stahl J, Brennan A, Caro JJ, Mar J, Möller J, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4. Value Health. 2012;15:821–7.View
To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. Both plasma Aβ42/40 ratio alone or combined...
BackgroundImmunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. We have developed the first active vaccine against the C-terminal end of Aβ40, ABvac40, and assessed its safety and tolerability in a phase I...
Lafuente1, Mar Buendía1, Virginia Pérez-Grijalba2, Itziar San Josè2, Marta Ibarria1, Miguel A Tejero4, Joan Giménez4, Isabel Hernández1, Lluís Tárraga1, Agustín Ruiz1, Mercè Boada1 and Manuel Sarasa2
Introduction The identification of early, preferably presymptomatic, biomarkers and true etiologic factors for Alzheimer’s disease (AD) is the first step toward establishing effective primary and secondary prevention programs. Consequently, the search for a relatively inexpensive and harmless biomarker for AD continues. Despite intensive research worldwide, to date there is no...
